Michael J Moon

Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2019, Bioorganic & medicinal chemistry letters.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Gang Shao, B. Darimont, J. Sensintaffar, 2013, Cancer discovery.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Journal of medicinal chemistry.

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Bioorganic & medicinal chemistry letters.